[Present status and future prospects of allergen immunotherapy in allergic rhinitis of China]

H F Lou; L Zhang

doi:10.3760/cma.j.cn115330-20210727-00487

[Present status and future prospects of allergen immunotherapy in allergic rhinitis of China]

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Apr 7;57(4):385-391. doi: 10.3760/cma.j.cn115330-20210727-00487.

[Article in Chinese]

Authors

H F Lou¹, L Zhang²

Affiliations

¹ Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing 100730, China Beijing Key Laboratory of Allergic Diseases, Beijing Institute of Otorhinolaryngology, Beijing 100005, China Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences (Beijing TongRen Hospital, Capital Medical University), Beijing 100730, China.
² Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing 100730, China Beijing Key Laboratory of Allergic Diseases, Beijing Institute of Otorhinolaryngology, Beijing 100005, China Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences (Beijing TongRen Hospital, Capital Medical University), Beijing 100730, China Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing 100730, China.

PMID: 35527429
DOI: 10.3760/cma.j.cn115330-20210727-00487

Abstract

过敏原特异性免疫治疗（allergenimmunotherapy，AIT）是在明确患者过敏原的前提下，让患者反复接触过敏原提取物，逐渐增加浓度和剂量，直至达到目标维持剂量，使患者对过敏原产生耐受，是目前唯一有望根治变应性鼻炎的对因治疗方法。近二十余年，国内学者在AIT临床实践和研究领域均取得较大进展。本文对我国变应性鼻炎的AIT现状进行了全面概述，并展望了我国AIT的发展方向。.

MeSH terms

Allergens
China
Desensitization, Immunologic*
Humans
Rhinitis, Allergic* / therapy

Substances

Allergens

Abstract

MeSH terms

Substances

Grants and funding